BioCentury Extra
Solace raises $15 million, names CEO
May 1, 2007 (no link available)

Neurology company Solace (Boston, Mass.) raised $15 million in a series A round led by Polaris Venture Partners and InterWest Partners. Founding investor PureTech also participated. The company's lead candidate, SLC022, is a small molecule modulator of glial cell activity. The compound has completed clinical trials in an undisclosed indication and will begin Phase II testing to treat neuropathic pain in 2008.

The company also named Eliot Forster CEO and a director. Forster was previously head of development for Europe and Asia at Pfizer (PFE). InterWest's Chris Ehrlich and Polaris' Kevin Bitterman joined Solace's board.